OVID - Ovid therapeutics Inc Stock Price, Fair Value and News

3.10USD+0.11 (+3.68%)Market Closed

Market Summary

USD3.10+0.11

Market Closed

3.68%

OVID Alerts

1 major insider buys recently.

OVID Stock Price

View Fullscreen

OVID RSI Chart

OVID Valuation

Market Cap

219.2M

Price/Earnings (Trailing)

-4.19

Price/Sales (Trailing)

756.21

EV/EBITDA

-3.71

Price/Free Cashflow

-4.78

OVID Price/Sales (Trailing)

OVID Profitability

EBT Margin

-17657.50%

Return on Equity

-59.61%

Return on Assets

-36.34%

Free Cashflow Yield

-20.91%

OVID Fundamentals

OVID Revenue

Revenue (TTM)

296.4K

OVID Earnings

Earnings (TTM)

-52.3M

Earnings Growth (Yr)

-33.18%

Earnings Growth (Qtr)

-36.17%

Breaking Down OVID Revenue

Last 7 days

-4.0%

Last 30 days

1.6%

Last 90 days

-16.7%

Trailing 12 Months

-14.1%

How does OVID drawdown profile look like?

OVID Financial Health

Current Ratio

9.55

OVID Investor Care

Shares Dilution (1Y)

0.31%

Diluted EPS (TTM)

-0.75

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	850.6K	198.5K	0	0
2022	167.0M	84.3M	42.9M	1.5M
2021	61.6M	110.5M	159.4M	208.4M
2020	0	0	0	12.6M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Ovid therapeutics Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Mar 18, 2024	levin jeremy m	bought	50,364	2.76	18,248	ceo
Feb 22, 2024	rona jeffrey a	acquired	-	-	28,125	cbfo
Feb 22, 2024	perone thomas michael	acquired	-	-	28,125	general counsel, secretary
Feb 22, 2024	tardio jason	acquired	-	-	28,125	chief operating officer
Dec 04, 2023	levin jeremy m	gifted	-	-	-1,146,550	ceo
Sep 12, 2022	tardio jason	sold	-37,289	2.15	-17,344	chief operating officer
Jul 01, 2022	takeda pharmaceutical co ltd	sold	-	-	-5,750,000	-
Jul 01, 2022	takeda pharmaceutical co ltd	acquired	-	-	5,750,000	-
Jul 14, 2021	rakhit amit	sold	-126,203	3.71	-34,017	president and cmo
Jul 14, 2021	rakhit amit	acquired	64,292	1.89	34,017	president and cmo

Which funds bought or sold OVID recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 25, 2024	SIMPLEX TRADING, LLC	new	-	3,000	3,000	-%
Apr 25, 2024	Bank of New York Mellon Corp	reduced	-7.74	-101,030	700,136	-%
Apr 24, 2024	Assenagon Asset Management S.A.	added	45.6	95,806	348,508	-%
Apr 23, 2024	AMALGAMATED BANK	reduced	-61.34	-11,000	6,000	-%
Apr 22, 2024	MetLife Investment Management, LLC	unchanged	-	-19,664	102,129	-%
Apr 19, 2024	Cutler Group LLC / CA	sold off	-100	-6,000	-	-%
Apr 15, 2024	Sound Income Strategies, LLC	new	-	18.00	18.00	-%
Apr 05, 2024	CWM, LLC	new	-	-	-	-%
Mar 22, 2024	PNC FINANCIAL SERVICES GROUP, INC.	new	-	32.00	32.00	-%
Mar 11, 2024	VANGUARD GROUP INC	added	0.79	-1,763,960	9,627,080	-%

Are Funds Buying or Selling OVID?

Are funds buying OVID calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own OVID

No. of Funds

OVID Alerts

1 major insider buys recently.

Unveiling Ovid therapeutics Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	madison avenue partners, lp	5.2%	3,648,509	SC 13G/A
Feb 14, 2024	levin jeremy m	9.4%	6,942,181	SC 13G/A
Feb 12, 2024	rubric capital management lp	7.52%	5,315,969	SC 13G/A
Jan 29, 2024	blackrock inc.	6.1%	4,319,918	SC 13G
Jul 31, 2023	madison avenue partners, lp	5.1%	3,609,054	SC 13G
Feb 14, 2023	levin jeremy m	10.0%	7,281,121	SC 13G/A
Feb 14, 2023	biotechnology value fund l p	5.2%	3,631,500	SC 13G/A
Feb 13, 2023	stonepine capital management, llc	0%	0	SC 13G/A
Feb 10, 2023	ecor1 capital, llc	8.7%	6,117,400	SC 13G/A
Feb 10, 2023	rubric capital management lp	9.69%	6,828,065	SC 13G

Recent SEC filings of Ovid therapeutics Inc

View All Filings

Date Filed	Form Type	Document
Apr 24, 2024	ARS	ARS
Apr 24, 2024	DEF 14A	DEF 14A
Apr 24, 2024	DEFA14A	DEFA14A
Mar 20, 2024	4	Insider Trading
Mar 08, 2024	10-K	Annual Report
Mar 08, 2024	8-K	Current Report
Feb 26, 2024	4	Insider Trading
Feb 26, 2024	4	Insider Trading
Feb 26, 2024	4	Insider Trading
Feb 26, 2024	4	Insider Trading

Peers (Alternatives to Ovid therapeutics Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	41.2B	6.8B	-2.42%	-17.04%	-8.75	6.02	-64.45%	-156.37%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	18.0B	1.8B	-7.18%	-26.90%	-41	9.87	76.23%	61.08%
BMRN	15.4B	2.5B	-8.70%	-12.49%	74.73	6.21	13.74%	186.89%
INCY	11.6B	3.7B	-9.54%	-29.84%	19.41	3.14	8.87%	75.42%
MID-CAP
APLS	6.0B	396.6M	-14.77%	-39.78%	-11.37	15.16	425.83%	18.94%
BBIO	4.4B	-	-19.35%	75.41%	-6.7	60.35	54.84%	-34.79%
AXSM	3.4B	270.6M	-9.32%	0.89%	-14.22	12.57	440.80%	-27.84%
ACAD	2.8B	726.4M	-8.24%	-18.54%	-44.9	3.79	40.45%	71.62%
ARWR	2.7B	240.7M	-22.93%	-36.73%	-9.23	12.18	-1.03%	-92.09%
SMALL-CAP
CPRX	1.8B	398.2M	-8.48%	-5.52%	24.58	4.41	85.90%	-14.05%
NVAX	569.6M	983.7M	-16.08%	-46.16%	-1.05	0.58	-50.36%	17.16%
CRBP	361.2M	881.7K	-3.23%	346.43%	-8.1	466.16	-77.61%	-5.33%
INO	247.0M	4.9M	-18.88%	12.93%	-1.83	50.76	-54.97%	51.71%
IBIO	6.1M	2.1M	-47.62%	62.96%	-0.22	2.14	-13.45%	66.37%

Ovid therapeutics Inc News

Latest updates

Ovid therapeutics Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3
Revenue	-	-	-	75,000	66,160	46,280	11,102	8,327	5,551	2,776	-	-	-	208,382,779	107,648,407	6,914,034
Operating Expenses	51.0%	18,329,908	12,137,804	14,246,982	14,958,465	12,219,192	12,814,958	14,304,287	17,712,472	-	26,353,665	11,681,734	14,312,826	31,825,463	27,294,429	23,317,696
S&GA Expenses	13.0%	7,688,024	6,805,213	8,248,216	8,343,748	6,662,985	7,631,705	8,257,617	9,880,203	-	8,264,051	6,764,341	6,629,158	15,576,554	10,410,643	7,442,401
R&D Expenses	99.6%	10,641,884	5,332,591	5,998,766	6,614,717	5,556,207	5,183,253	6,046,670	7,832,269	-	18,089,614	4,917,393	7,683,668	16,248,909	16,883,786	15,875,295
EBITDA Margin	-8.0%	-174	-161	-244	-59.79	-35.69	-1.60	-0.81	-0.54	0.74	0.60	0.81	1.12	1.88	-	-
Income Taxes	-	-	-	-	-	-25,000	-	-	50,000	-	-349,714	-294,829	1,473,084	500,277	-	-
Earnings Before Taxes	-36.2%	-15,322,034	-11,252,386	-12,408,330	-13,356,209	-11,529,788	-11,967,771	-14,588,414	-16,058,056	-	-26,349,762	-11,679,077	-14,315,343	176,507,584	-22,029,501	-16,424,789
EBT Margin	-7.8%	-176	-163	-248	-60.47	-36.03	-1.61	-0.82	-0.54	0.74	0.60	0.81	1.12	1.88	-	-
Net Income	-36.2%	-15,322,034	-11,252,386	-12,408,330	-13,356,209	-11,504,788	-11,967,771	-14,588,414	-16,108,056	-	-26,000,048	-11,384,248	-15,788,427	176,007,307	-22,029,501	-16,424,789
Net Income Margin	-7.9%	-176	-163	-247	-60.44	-36.05	-1.60	-0.81	-0.55	0.74	0.59	0.80	1.10	1.87	-	-
Free Cashflow	-18.3%	-11,913,706	-10,073,859	-11,695,537	-12,125,820	-9,268,544	-12,694,973	-14,328,508	-20,132,354	-12,160,462	-12,160,462	-10,894,066	-19,405,376	160,887,569	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	15.2%	144	125	136	143	155	165	177	191	195	207	218	237	76.00	92.00	45.00	62.00	81.00	41.00	55.00	67.00	48.00
Current Assets	19.5%	110	92.00	102	120	131	140	156	170	190	205	216	237	75.00	90.00	44.00	61.00	80.00	39.00	54.00	63.00	44.00
Cash Equivalents	-52.9%	27.00	57.00	72.00	63.00	45.00	60.00	75.00	169	190	202	212	233	72.00	87.00	41.00	27.00	42.00	38.00	47.00	55.00	36.00
Net PPE	-10.2%	1.00	1.00	1.00	1.00	1.00	1.00	1.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Liabilities	136.9%	56.00	24.00	26.00	22.00	23.00	23.00	25.00	26.00	15.00	10.00	11.00	16.00	32.00	28.00	15.00	10.00	11.00	11.00	9.00	9.00	9.00
Current Liabilities	32.4%	11.00	9.00	10.00	7.00	7.00	-	-	-	15.00	10.00	11.00	16.00	22.00	18.00	15.00	10.00	11.00	10.00	9.00	8.00	9.00
Shareholder's Equity	-13.3%	88.00	101	111	121	132	142	152	165	180	197	207	221	44.00	64.00	30.00	51.00	70.00	30.00	45.00	57.00	39.00
Retained Earnings	-5.9%	-277	-262	-251	-238	-225	-214	-202	-187	-171	-145	-133	-118	-294	-272	-255	-233	-213	-196	-179	-166	-152
Additional Paid-In Capital	0.5%	366	364	362	360	358	356	354	352	351	342	341	339	338	336	286	285	283	226	225	224	191
Shares Outstanding	0.0%	71.00	71.00	71.00	70.00	70.00	70.00	70.00	70.00	70.00	67.00	67.00	66.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	191	-	-	-	125	-	-	-	217	-	-	-	294	-	-	-	26.00	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	-17.8%	-11,900	-10,100	-11,700	-12,100	-9,175	-12,676	-13,288	-20,086	-11,998	-10,872	-19,416	160,899	-14,509	-1,469	-17,193	-18,411	-16,888	-9,494	-11,841	-12,866	-10,965
Share Based Compensation	9.7%	1,789	1,631	1,949	1,917	1,730	1,782	1,720	1,325	1,315	1,162	1,257	1,320	2,051	2,616	1,555	1,303	1,127	1,184	1,252	1,643	1,731
Cashflow From Investing	-1012.9%	-48,516	-4,359	20,066	30,229	-4,169	-1,960	-80,677	-1,076	-161	-64.03	-1,583	-11.51	-90.48	-38.30	30,941	3,836	-35,008	-18.58	4,995	-8.97	16,942
Cashflow From Financing	13324.6%	30,033	224	211	67.00	-43.60	82.00	110	33.00	109	549	116	130	-232	47,120	169	16.00	55,886	59.00	-391	30,986	2*

OVID Income Statement

2023-12-31

Consolidated Statements of Operations - USD ($)	12 Months Ended
Consolidated Statements of Operations - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Revenue:
Total revenue	$ 391,695	$ 1,502,748
Operating expenses:
Research and development	28,587,884	24,618,399
General and administrative	31,085,274	32,432,510
Total operating expenses	59,673,158	57,050,909
Loss from operations	(59,281,464)	(55,548,161)
Other income (expense), net	6,942,505	1,379,132
Loss before provision for income taxes	(52,338,959)	(54,169,029)
Provision for income taxes	0	0
Net loss	$ (52,338,959)	$ (54,169,029)
Net loss per share, basic (in USD per share)	$ (0.74)	$ (0.77)
Net loss per share, diluted (in USD per share)	$ (0.74)	$ (0.77)
Weighted-average common shares outstanding, basic (in shares)	70,580,604	70,424,819
Weighted-average common shares outstanding, diluted (in shares)	70,580,604	70,424,819

OVID Balance Sheet

2023-12-31

Consolidated Balance Sheets - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 27,041,517	$ 44,867,846
Marketable securities	78,791,858	84,133,565
Prepaid expenses and other current assets	3,764,332	2,379,280
Total current assets	109,597,707	131,380,691
Long-term equity investments	17,625,620	5,622,547
Restricted cash	1,930,753	1,930,753
Right-of-use asset, net	13,894,376	14,922,669
Property and equipment, net	768,753	1,147,963
Other assets	209,574	261,191
Total assets	144,026,783	155,265,814
Current liabilities:
Accounts payable	3,702,936	1,952,910
Accrued expenses	6,525,235	4,504,669
Current portion, lease liability	1,246,119	533,946
Total current liabilities	11,474,290	6,991,525
Long-term liabilities:
Lease liability	14,755,606	16,001,725
Royalty monetization liability	30,000,000	0
Total liabilities	56,229,896	22,993,250
Stockholders' equity:
Preferred stock, $0.001 par value; 10,000,000 shares authorized; Series A convertible preferred stock, 10,000 shares designated, 1,250 shares issued and outstanding at December 31, 2023 and 2022	1	1
Common stock, $0.001 par value; 125,000,000 shares authorized; 70,691,992 and 70,466,885 shares issued and outstanding at December 31, 2023 and 2022, respectively	70,692	70,467
Additional paid-in-capital	365,590,993	357,770,825
Accumulated other comprehensive income (loss)	702	(42,187)
Accumulated deficit	(277,865,501)	(225,526,542)
Total stockholders' equity	87,796,887	132,272,564
Total liabilities and stockholders' equity	$ 144,026,783	$ 155,265,814

About Ovid therapeutics Inc

Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing soticlestat, a novel cholesterol 24 hydroxylase inhibitor, which is in Phase 3 clinical trials for the potential treatment of patients with resistant epilepsies; OV329, a GABA aminotransferase inhibitor which is in Phase 1 clinical trials for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule direct activator of the KCC2 transporter, which is in Phase 1 clinical trials for treating epilepsies. It also develops OV815, currently under preclinical stage, that focuses on the mutations associated with KIF1A-associated neurological disorder (KAND); OV825, currently under preclinical stage, which has advanced to potential candidate lead identification for the rare neurodevelopmental condition HNRNPH2 (Bain Syndrome); and OV882, currently under preclinical stage, a short hairpin RNA gene therapy for the treatment of Angelman syndrome. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, and Northwestern University, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.

CEO	Dr. Jeremy Max Levin Ba Zoology, Dphil, Mb Bchir
WEBSITE	ovidrx.com
INDUSTRY	Biotechnology
EMPLOYEES	40

Ovid therapeutics Inc Frequently Asked Questions

What is the ticker symbol for Ovid therapeutics Inc? What does OVID stand for in stocks?

OVID is the stock ticker symbol of Ovid therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Ovid therapeutics Inc (OVID)?

As of Fri Apr 26 2024, market cap of Ovid therapeutics Inc is 219.2 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of OVID stock?

You can check OVID's fair value in chart for subscribers.

What is the fair value of OVID stock?

You can check OVID's fair value in chart for subscribers. The fair value of Ovid therapeutics Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Ovid therapeutics Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for OVID so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Ovid therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether OVID is over valued or under valued. Whether Ovid therapeutics Inc is cheap or expensive depends on the assumptions which impact Ovid therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for OVID.

What is Ovid therapeutics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Apr 26 2024, OVID's PE ratio (Price to Earnings) is -4.19 and Price to Sales (PS) ratio is 756.21. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. OVID PE ratio will change depending on the future growth rate expectations of investors.